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IMMUNOCONTRACEPTION AND POSSIBLE APPLICATION IN WILDLIFE DAMAGE
MANAGEMENT
LOWELL A. MILLER, U.S. Department of Agriculture, Denver Wildlife Research Center, Denver, CO 80225
Abstract: lmmunocontraception technology appears to have viable application in wildlife damage management. However, ad-
ministration of these vaccines is presently performed by syringe injection or remote delivery by darts or bio-bullets. In order for
immunocontraception to be successful for broad scale application to free-roaming animals, the vaccine must be delivered in an
oral form. Recent advances in molecular biology, immunology, and pathology of mucosal infection gives us tools to develop
effective oral vaccines. Oral immunocontraceptive vaccine encapsulated in adhesive liposomes or non-virulent live vectors
holds promise as a practical approach for immunocontraception of free-roaming wildlife. Issues of safety, species specificity,
regulatory constraints, and field application of the vaccine will need to be addressed.
Pages 27-30 in R.E. Masters and J.G. Huggins, eds. Twelfth
Great Plains Wildl. Damage Control Workshop Proc, Pub-
lished by Noble Foundation, Ardmore, Okla.
Key words: immunocontraception, oral vaccine, over-population, population control, wildlife damage management.
Over-population is a worldwide problem in humans,
mammals, and birds. In the United States (US) it is often asso-
ciated with controversy; in humans it often concerns the issue
of abortion. In the animal arena, the issue may be associated
with killing of animals. Residues from pesticides or steroids
entering the food chain are also controversial. Still, the need
for population control continues. New insights into hormonal
control of reproduction and advances in vaccine technology
have brought to the forefront the development of birth control
vaccines, technically known as immunocontraceptives. Con-
siderable research has demonstrated that fertility can be con-
trolled by producing antibodies to key reproductive hormones,
thus inactivating them (Talwar 1987). The ideal control is to
develop a vaccine that would prevent conception, while not
affecting other reproductive functions (such as ovulation and
secondary sex characteristics.)
Overpopulation of white-tailed deer (Odocoileus
virginianus) is an increasing problem in some sections of the
US. Deer populations continue to increase in many northeast-
ern states despite an increasing number of hunters and more
liberal harvest regulations. A1990 national survey of Animal
Damage Control (ADC) program directors showed that ungu-
lates were a significant problem in 35 of the 50 states resulting
in damage to forest and agricultural crops and safety hazards
related to motor vehicle incidents (Packam and Connolly 1992).
In 1994, the US white-tailed deer population was estimated to
be 15 million and growing, the highest level this century (Curtis
and Richmond 1994). It is important to keep the deer popula-
tion in balance with its natural habitat.
Traditionally, sport hunting has been used to manage
white-tailed deer populations. Encroachment of man into ru-
ral areas (e.g., building new homes on 0.8-1.2 ha [2 to 3 ac])
cleared areas has increased the amount of land closed to hunt-
ing. Two-thirds of available hunting lands exist in private own-
ership. This prompts the need to seek alternative methods of
population control.
Several alternatives to public hunting have been used.
They include translocation, fencing, repellents, lure crops, and
crop compensation. These methods have either been ineffec-
tive, impractical, or too expensive to be considered as viable
alternatives to hunting programs.
IMMUNOCONTRACEPTION
Contraception has been studied as a viable
bioalternative to current deer population management meth-
ods through the use of synthetic steroids (Roughton 1979).
Several attempts to control deer reproduction with synthetic
estrogens and progestin have either been ineffective or imprac-
tical for field use. Synthetic estrogens and progestins are ef-
fective as contraceptives, however, the need to feed the steroids
daily make them impractical in field situations. Steroids are
also carried through the food chain which makes them eco-
logically undesirable.
Recent advances in molecular biology and immunol-
ogy have provided us new tools such as immunocontraception
as a means of contraception. Immunocontraception vaccines
control fertility by stimulating the production of antibodies
against gamete proteins or reproductive hormones. These an-
tibodies interfere with the normal biological activity of these
reproductive proteins or hormones (Talwar 1987).
This approach is a natural process in the sense that
antibodies induced in the target animal interfere with repro-
duction without the need for constant medication with syn-
thetic compounds.
Immunocontraception holds the promise to overcome
the drawbacks found in the use of steroids for contraception.
The immunological approach to contraception is attractive
because it requires only periodic vaccination (Turner and
Kirkpatrick 1991).
28 IMMUNOCONTRACEPTION • Miller
Reproductive Hormones and Proteins
Gonadotropin releasing hormone (GnRH), produced
in the brain by the hypothalamus, controls the release of the
pituitary reproductive hormones; follicle stimulating hormone
(FSH) and luteinizing hormone (LH). These hormones in turn
control the hormonal function of the gonads (ovaries and tes-
tes). Antibodies produced to this hypothalamic hormone will
reduce the circulating level of biologically active GnRH,
thereby reducing the release of subsequent reproductive hor-
mones. The reduction of these hormones results in atrophy of
the gonads, resulting in infertility of both sexes.
The zona pellucida (ZP) is an acellular glycoprotein
surrounding the oocyte, located between the oocyte and the
granulosa cells on the outer surface. Antibodies to this glyco-
protein layer result in infertility by one or both of these ac-
tions: 1) blocking sperm binding to the ZP layer, and 2)
interference with oocyte maturation. In order for a sperm to
fertilize the egg, it must first bind to a receptor on the ZP. An
enzyme in the sperm breaks down the ZP and allows the sperm
passage into the egg. Antibodies to the ZP prevent fertilization
by interfering with the binding of the sperm, or the ZP anti-
bodies can interfere with oocyte/granulosa cell communica-
tion and result in the death of the developing oocyte (Dunbar
and Schwoebel 1988).
Antibodies can be produced to sperm head proteins
which normally bind to the ZP receptor on the oocyte. These
antibodies are produced in the female and are available to bind
to sperm present in the oviduct. Sperm protein
immunocontraception is being researched for contraception of
the red fox (Vulpes vulpes) and the rabbit (Sylvilagus spp.) in
Australia (Morell 1993, Tyndal-Biscoe 1991).
Chorionic gonadotropin (CG) hormone, which is pro-
duced by the implanting embryo, induces the corpus luteum to
continue production of the progesterone required for mainte-
nance of pregnancy. Antibodies to CG reduce blood circula-
tion levels of this hormone and therefore prevent implantation
of the fertilized egg. Reproduction can be blocked at many
sites in the reproductive process, however, the above examples
represent the most researched sites (Griffin 1992, Jones 1983).
The Immune Self
The neonate vertebrate immune system develops a
recognition of "self proteins, carbohydrates, and hormones.
This self recognition is essential for survival. Antibodies against
"self is an abnormal destructive process as demonstrated in
diseases like multiple sclerosis and arthritis. However, the pro-
duction of antibodies against pathogenic bacteria and viruses
is essential for survival. The respiratory and intestinal mucosal
surfaces contain various white blood cells (lymphocytes) re-
sponsible for generating specific immune responses. In the
small intestine, groups of lymphoid cells known as Peyer's
patches (PP) serve as "quality control inspectors" sampling
bits of food proteins and microorganisms as they pass through.
The entire immune system is in constant surveillance to deter-
mine self versus foreign and, as in the digestive tract, particles
and organisms are examined and either tolerated or attacked
by antibodies.
Anti-fertility vaccines are directed against self repro-
ductive antigens (hormones or proteins) to which the recipient
normally is immunologically tolerant. These antigens are made
non-self or foreign by coupling them to a protein that is for-
eign to the animal. As the animal samples the conjugated self-
foreign protein, antibodies are produced to its own reproductive
proteins and hormones. This induced immune response against
self is the key to immunocontraception. Infertility lasts as long
as there are sufficient antibodies to interfere with the biologi-
cal activity of the targeted hormone or reproductive protein.
This duration is usually 1 to 2 years.
VACCINE ADMINISTRATION
Traditional delivery of vaccines has been by subcuta-
neous or intramuscular (IM) injection. In order to achieve this
form of delivery in the free roaming animal, the vaccine must
be delivered remotely by a dart or a bio-bullet (Garrott et al.
1992, Kirkpatrick et al. 1990, Turner et al. 1992). While this
method may be effective in certain confined locations, it proves
impractical when dealing with wildlife populations in large
open areas.
Oral delivery of vaccines has received little attention
for human vaccination because it has required larger quanti-
ties of vaccines and has been less predictable than subcutane-
ous and IM routes. In mammals, oral immunization takes place
in the pharyngeal immune follicles including the tonsils, and
in the small intestine. There are thousands of immune follicles
throughout the small intestine with a higher concentration in
the distal portion in most species. Vaccines, being protein in
nature, are rapidly digested in the stomach when given orally,
therefore, immunization must occur in the pharyngeal area or
the vaccine needs a protective capsule to survive the stomach
and be released in the small intestine (McGhee et al. 1992).
Enteric-coated capsules are commonly used for de-
livery of drugs to the small intestine. Enteric capsules are re-
sistant to acid, but are soluble in the alkaline solution of the
small intestine. They provide only one-half of the formula of
effective antigen delivery in the small intestine, that is protec-
tion from the stomach acid, since they generally cannot be made
small enough to be taken up by the PP. Also, there is another
problem with enteric-coated vaccines. They can get the pro-
tein past the stomach, dissolve, and release the antigen in the
small intestine, but proteolytic enzymes in the small intestine
may digest these proteins into non-immunogenic peptides be-
fore they are absorbed by the immune cells. The safest way to
deliver the antigen orally is to protect it until it is taken up by
the PP and delivered to macrophages. Combining 2 approaches:
1) enteric coating using delivery vehicles that slow the intesti-
nal degradation of the antigen and 2) targeting vaccine design
to have enhanced attachment to the immune follicles in the
small intestine, could lead to an effective antigen uptake and
potentiation of mucosal immune response.
Recent understanding of the mechanisms by which
pathogenic virus and bacteria colonize and infect the intesti-
nal tract has given us new tools to develop successful, safe,
non-live or attenuated live oral vaccines. For example, a bac-
teria must survive the stomach's acid and proteolytic enzymes
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in order to successfully infect the small intestine. After surviv-
ing the stomach, it must have surface adhesive properties al-
lowing it to adhere to and colonize the intestinal wall, resulting
in an infection. Bacteria without these adhesive properties will
be carried out of the gut with the undigested food material.
Liposomes are spherical, artificial biological mem-
branes made up of phospholipids and cholesterol. The lipo-
some membrane contains lipids, chosen for their stability in
the gastrointestinal tract, which protect the antigen placed in-
side during synthesis from gastrointestinal degradation. Cho-
lesterol in the membrane stabilizes it and makes it attractive to
macrophages in the PP where the liposome is avidly taken up
because of the membrane's lipophilic nature. Because of the
nature of the membrane, the liposome simulates a microbial
cell when presented to the immune system. The liposome acts
as an antigen microcarrier capable of targeting the antigen di-
rectly to the PP.
However, before the liposome can be taken up by the
macrophages, it must bind to the mucosal surface of the intes-
tine, otherwise it will be swept out with the undigested food
material. This mucosal adhesive property increases the mu-
cosal uptake resulting in greater efficiency and a smaller oral
vaccine dose. The most common liposome adhesive is the bac-
terial lectin cholera toxin (CT), a member of a family of en-
terotoxins produced by several strains of enteropathogenic
bacteria (Holmgren et al. 1992). Lectins have multiple bind-
ing sites and can bind to receptors on the liposome as well as
intestinal receptors.
Recent advancements in molecular biology and im-
munology have provided us with new tools such as "live vec-
tors" as delivery vehicles. The most prominent use of this
technology in wildlife management is the use of live vaccinia
virus to orally deliver rabies vaccine to raccoons (Procyon lotor)
and foxes. The attenuated vaccinia virus, a member of the pox
viruses, was used as a vaccine against small pox for over 20
years. Using recombinant genetic engineering, the gene respon-
sible for the encoding of the glycoprotein rabies virus was in-
serted into the vaccinia virus by the Wistar Institute. This
recombinant pox virus, when given orally, is able to vaccinate
the target animal against rabies. The tonsil lymphoid tissue is
thought to initiate the immune response in these target ani-
mals.
IMMUNOCONTRACEPTTVE STUDIES AT DWRC
In 1991, Denver Wildlife Research Center (DWRC)
initiated research to develop immunocontraceptive vaccines
to address problems caused by damaging species of wildlife.
The research and development focus has been on synthetic
vaccines for oral immunization of white-tailed deer, wild rats
{Rattus spp.), starlings (Sturnus vulgaris) and brown-headed
cowbirds (Molothrus ater). If funds are available, other spe-
cies will be added to the research.
Initial delivery of vaccines was done by injecting cap-
tive animals with various preparations as mentioned in this
paper. Rats sterilized with GnRH vaccine remained sterile for
over a year. White-tailed deer vaccinated with ZP of porcine
origin remained sterile for 1-3 years. By vaccinating with an
avian specific GnRH, we have shut down spring production of
testosterone in male brown-headed cowbirds.
Our initial work centered on development of the vac-
cine and measuring immune and hormonal levels in response
to systemic vaccination. Our goal is to deliver the vaccine orally.
The DWRC has successfully sterilized Norway rats (Rattus
norvegicus) by oral immunization with GnRH encapsulated in
an adhesive liposome which was designed at DWRC.
EVALUATING THE EFFECTIVENESS OF THE
CONTRACEPTIVE VACCINE
In addition to breeding trials, effectiveness of
immunocontraceptive vaccines is assessed by measuring se-
rum progesterone, testosterone, and antibody titers. Reduction
in hormone level as well as elevated antibody levels should
correlate with sterility of the animal. All immunocontraception
vaccines presently being studied result in some behavioral
changes. These behavioral responses vary from total reduc-
tion in sexual function in both males and females to multiple
estrus in the female immunized with ZP.
ORAL VACCINE DELIVERY SYSTEM
The rapidly expanding potential of recombinant DNA
technology allows the use of recombinant bacteria or viral vec-
tors to deliver the vaccine to wildlife. However, it is impracti-
cal to inject every animal either under restraint or remotely by
a dart gun; therefore, oral vaccination represents the only prac-
tical method for mass vaccination of free roaming animals.
The oral vaccine and/or bait should be species specific, and
must be delivered to the tonsils (pharyngeal tissue) or the
Peyer's patches in the small intestine. Oral vaccination is gen-
erally less efficient than an injection in relation to the quantity
of antigen used. Recombinant live bacteria or viral vectors are
probably the only effective way to deliver these antigens. The
safety of the oral vectors will need to be proven to the public.
Recent worldwide interest in oral vaccines for chol-
era toxin and the AIDS virus is rapidly providing technology
and dialogue to the above questions that can be applied to the
animal vaccine arena.
PUBLIC ISSUES
A number of issues must be addressed before a pro-
gram is developed to administer these vaccines. Certain ani-
mal welfare and animal rights issues must be answered. Is it
moral to alter the animal's reproductive system? Is there any
unusual pain involved with vaccination? Are we changing the
usual behavior of these animals? Can any residue vaccine be
carried through the food chain? What are the effects on non-
target animals? Will non-target animals, perhaps an endangered
species, become sterilized?
What are the human safety issues involved in such a
program? Can a human accidently ingest the oral vaccine and
become sterilized? How will public education on technology
be organized? After a vaccine has been produced in produc-
tion scale, who controls the delivery of the vaccine? Is the use
of the vaccine to be controlled at the federal, state, or local
government level?
